PR95756

BEIJING, April 29, 2022 /PRNewswire=KYODO JBN/ --

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it

has entered into an evaluation and option agreement with Merck to grant them a

sole license to evaluate Biocytogen's proprietary antibodies against at least

three distinct targets with an option to acquire some of the assets at a later

date for therapeutic product development for all uses worldwide.

Under the agreement, Biocytogen will provide Merck antibodies directed against

at least three targets specified by them from Biocytogen's Project Integrum

(also called HiTS Platform), which are generated by leveraging Biocytogen's

proprietary RenMiceTM Platform. Merck will carry out feasibility tests and be

responsible for further development and commercialization of the products if

exercising an option. Additional targets subject to mutual discretion may be

included under this agreement.

Dr. Yuelei Shen, President and CEO of Biocytogen, said: "Thanks to Merck's

recognition of our proprietary platform and antibody discovery capabilities, we

believe that differentiated candidates generated from our innovative models and

discovery platform can quickly advance novel antibody-based therapeutics. Our

RenMiceTM-based Project Integrum aims to discover antibodies against more than

1,000 targets. We welcome collaboration with partners worldwide to realize the

full potential of this platform."

About Biocytogen

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotech company that

drives the research and development of new drugs with innovative technologies.

The company is committed to becoming a global headstream of new drugs to bring

benefits to patients worldwide. Based on the fully human antibody RenMabTM and

RenLiteTM mice for fully human antibody production with robust humoral

responses, highly diverse antibody repertoires and superior affinity,

Biocytogen has integrated its platforms in monoclonal and bispecific antibody

development platforms, in vivo drug efficacy screening platforms and strong

clinical development ability to streamline the entire drug development process.

Biocytogen has launched Project Integrum, the world's first large-scale

antibody discovery screening program adopting an evidence-based in vivo

efficacy screening methodology to concurrently generate and screen antibodies

against over 1,000 potential druggable targets, most of which have not been

explored in clinical trials yet. With the implementation of Project Integrum,

Biocytogen has entered ongoing collaborations with dozens of partners worldwide

to produce many first-in-class and/or best-in-class antibody drugs.

Biocytogen's pipeline includes 12 core products among which 2 products are in

phase II multi-regional clinical trials (MRCTs) and 2 products are in phase I.

Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai,

Boston, USA and Heidelberg, Germany.

About Merck

Merck, a leading science and technology company, operates across healthcare,

life science and electronics. Around 60,000 employees work to make a positive

difference to millions of people's lives every day by creating more joyful and

sustainable ways to live. From advancing gene editing technologies and

discovering unique ways to treat the most challenging diseases to enabling the

intelligence of devices – the company is everywhere. In 2021, Merck generated

sales of € 19.7 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to

Merck's technological and scientific advances. This is how Merck has thrived

since its founding in 1668. The founding family remains the majority owner of

the publicly listed company. Merck holds the global rights to the Merck name

and brand. The only exceptions are the United States and Canada, where the

business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma

in life science, and EMD Electronics.

Source:Biocytogen

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=420247